Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible

Dworzak, Michael; Gaipa, Giuseppe; Ratei, Richard; Veltroni, Marinella; Schumich, Angela; Maglia, Oscar; Karawajew, Leonid; Benetello, Allessandra; Pötschger, Ulrike; Husak, Zvenyslava; Gadner, Helmut; Biondi, Andrea; Ludwig, Wolf‐Dieter; Basso, Giuseppe

doi:10.1002/cyto.b.20430

Cited by 137 publications

(161 citation statements)

References 28 publications

Supporting

Mentioning

145

Contrasting

Unclassified

Order By: Relevance

“…27 MFC is used more extensively Prognostic value MRD levels at HSCT by MFC in ALL J Sanchez-Garcia et al at transplantation centers probably because of the availability of multicolor flow-cytometers. However, MFC has disadvantages: fluctuations in Ag expression and lack of expertise interpretation of results.…”

Section: Discussionmentioning

confidence: 99%

Quantification of minimal residual disease levels by flow cytometry at time of transplant predicts outcome after myeloablative allogeneic transplantation in ALL

Sánchez‐García

Serrano

Serrano‐López

et al. 2012

Bone Marrow Transplant

View full text Add to dashboard Cite

The potential impact on patient outcome of different Minimal residual disease (MRD) levels at time of transplant in patients with lymphoblastic leukemia undergoing allogeneic hematopoietic SCT (HSCT) remains uncertain. In this study, we quantified MRD levels at time of transplant using multiparameter flow cytometry (MFC). Mononuclear cells from marrow aspirates were obtained from 102 adult and child patients before their conditioning regimen. Quantification of MRD levels was carried out by detecting patient-specific leukemia-associated immunophenotypes using four-color MFC. Thirty patients exhibited measurable levels of MRD at the time of transplant, with low levels (0.01 to p0.1%) in 12 cases, intermediate levels (40.1 to p1%) in 8 cases and high levels (41%) in 10 cases. The leukemia-free survival (LFS) rates were 65.9±7.0%, 42.9±15.7% and 0% for negative, low levels p0.1% and intermediate-high levels 40.1%, respectively (Po0.001, log-rank test). Overall survival (OS) was 52.3 ± 7.6%, 28.6 ± 13.8% and 0% for MRD-negative, low levels p0.1% and intermediate-high levels 40.1%, respectively (Po0.001, log-rank test). Multivariate Cox analysis confirmed that detection of leukemia cells by flow cytometry at transplant was the most significantly adverse factor for OS, LFS and EFS after transplant.

show abstract

Section: Discussionmentioning

confidence: 99%

Quantification of minimal residual disease levels by flow cytometry at time of transplant predicts outcome after myeloablative allogeneic transplantation in ALL

Sánchez‐García

Serrano

Serrano‐López

et al. 2012

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…33,64 The EuroFlow Consortium works on full standardization of instrument setups, sample preparation, immunostaining procedures, fluorochromes and eight-color antibody panels, as well as bioinformatics-assisted expert independent automated analysis of the acquired data. [65][66][67] The major advantage of FCM is its rapidity, which allows result reporting within 1 day.…”

Section: Multiparameter Fcmmentioning

confidence: 99%

“…Flow cytometric and molecular methods that allow sensitive detection and specific quantification of residual leukemic cells have been developed. [28][29][30][31][32][33][34][35][36][37][38][39][40] Standardization of methodologies and definitions of common MRD terms become increasingly important, not only to ensure comparability of MRD data between different MRD laboratories within a single MRD-based treatment protocol but also to provide a sound basis for the comparison of MRD results between different treatment protocols, including those that evaluate the effectiveness of new agents.…”

Section: Introductionmentioning

confidence: 99%

Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008

et al. 2009

View full text Add to dashboard Cite

Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the basis of its high prognostic value for predicting outcome and the possibilities for implementation of MRD diagnostics in treatment stratification. Therefore, there is an increasing need for standardization of methodologies and harmonization of terminology. For this purpose, a panel of representatives of all major European study groups on childhood and adult ALL and of international experts on PCR-and flow cytometry-based MRD assessment was built in the context of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. The panel summarized the current state of MRD diagnostics in ALL and developed recommendations on the minimal technical requirements that should be fulfilled before implementation of MRD diagnostics into clinical trials. Finally, a common terminology for a standard description of MRD response and monitoring was established defining the terms 'complete MRD response', 'MRD persistence' and 'MRD reappearance'. The proposed MRD terminology may allow a refined and standardized assessment of response to treatment in adult and childhood ALL, and provides a sound basis for the comparison of MRD results between different treatment protocols.

show abstract

“…Immunostaining with fluorochrome-labelled monoclonal antibodies was done as described elsewhere (23). A wide panel of monoclonal antibodies was used, including antibodies against CD11a, CD34, CD41, CD61, CD19, CD7, CD33, CD13, CD15, CD117, MPO, CD45, CD56, and HLA-DR. For staining CD11a, we uniformly used the CD11a/LFA-1 PE-conjugated mouse antibody (Clone HI111, Becton Dickinson [BD] PharMingen).…”

Section: Flow Cytometric Analysismentioning

confidence: 99%

Blast cell deficiency of CD11a as a marker of acute megakaryoblastic leukemia and transient myeloproliferative disease in children with and without Down syndrome

Boztug

Schumich

Pötschger

et al. 2013

Cytometry Part B Clinical

Self Cite

View full text Add to dashboard Cite

Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible

Abstract: Conclusion: MRD-evaluation by FCM in ALL can be standardized for reliable multicentric assessment in large trials. q

Cited by 137 publications

References 28 publications

Quantification of minimal residual disease levels by flow cytometry at time of transplant predicts outcome after myeloablative allogeneic transplantation in ALL

Quantification of minimal residual disease levels by flow cytometry at time of transplant predicts outcome after myeloablative allogeneic transplantation in ALL

Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008

Blast cell deficiency of CD11a as a marker of acute megakaryoblastic leukemia and transient myeloproliferative disease in children with and without Down syndrome

Contact Info

Product

Resources

About